๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma

โœ Scribed by Yong-Suk Chung; Yoshito Yamashita; Tohru Inoue; Tasuku Matsuoka; Bunzo Nakata; Naoyoshi Onoda; Kiyoshi Maeda; Tetsuji Sawada; Yasuyuki Kato; Tetsuhiko Shirasaka; Michio Sowa

Publisher
John Wiley and Sons
Year
1997
Tongue
English
Weight
85 KB
Volume
80
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

โœฆ Synopsis

City Uni-11 cases, for an overall response rate of 50%. Patients with good performance versity Medical School, Osaka, Japan.

status (PS) (0-1) and differentiated histologic type showed higher response rates (50.0% and 63.6%, respectively) than patients with poor PS (2 or 3) and undifferenti-2 Institute for Pathogenic Biochemistry in Medicine, Taiho Pharmaceutical Company, Tokyo, ated histologic type (28.6% and 35.3%, respectively), although there were no sig-Japan.

nificant differences. Patients with low serum levels of immunosuppressive acidic protein (IAP) showed a significantly higher response rate (71.4%) than those with high IAP levels (0%). Toxic effects included leukopenia, thrombocytopenia, nausea, and vomiting; these were not life-threatening and did not require treatment interruption.

CONCLUSIONS.

FP therapy is a promising regimen for patients with advanced and recurrent gastric adenocarcinoma. Serum levels of IAP may predict chemosensitivity.

๐Ÿ“œ SIMILAR VOLUMES

Palliative treatment with low-dose conti
Palliative treatment with low-dose continuous infusion 5-fluorouracil in recurrent and/or metastatic undifferentiated nasopharyngeal carcinoma type
โœ Abderrahim Fandi; Abdelkrim Taamma; Nacer Azli; Mounir Bachouchi; Bashar Yanes; ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 59 KB ๐Ÿ‘ 1 views

## Background: Low-dose protracted continuous infusion (ci) 5-fluorouracil (5-fu), as proposed by lokich et al, has been reported to be active and well tolerated in colorectal and breast cancers. we initiated a phase ii trial with ci 5-fu in heavily pretreated undifferentiated carcinoma of the naso

Cisplatin, continuous-infusion 5-fluorou
Cisplatin, continuous-infusion 5-fluorouracil, and intermediate-dose methotrexate in the treatment of unresectable non-small cell carcinoma of the lung
โœ Catherine A. Wheeler; Lawrence N. Shulman; Steven E. Come; Lowell E. Schnipper; ๐Ÿ“‚ Article ๐Ÿ“… 1991 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 377 KB ๐Ÿ‘ 1 views

Forty-one patients with unresectable non-small cell carcinoma of the lung (NSCCL) were treated with cisplatin 20 mg/m2/d for 5 days as a daily bolus injection, 5-fluorouracil 800 mg/m2/d by continuous infusion for 5 days, and intermediate-dose methotrexate 200 mg/m2 on days 15 and 22 of a 28-day cyc

Evaluation of low dose continuous infusi
Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group study
โœ Julie A. Kish; Michael Wolf; E. David Crawford; Joseph T. Leimert; Anton Buesche ๐Ÿ“‚ Article ๐Ÿ“… 1994 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 289 KB ๐Ÿ‘ 2 views

Background. The response rate of metastatic renal cell cancer to cytotoxic therapy over the last 10 years has been 5.6%. Low dose continuous 5-fluorouracil(5-FU) has demonstrated efficacy in other cytotoxic refractory tumors, such as pancreas, colorectal, and recurrent breast. The Southwest Oncology

Paclitaxel, 5-fluorouracil, and cisplati
Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma
โœ Yeul H. Kim; Sang W. Shin; Byung S. Kim; Jin H. Kim; Jong G. Kim; Young J. Mok; ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 86 KB ๐Ÿ‘ 2 views

## Background: Although the clinical efficacy of paclitaxel in the treatment of gastric carcinoma has not been clearly defined, recent reports have suggested a possible role in the treatment of upper gastrointestinal carcinomas in vitro and in vivo. in this study, the authors evaluated the efficacy